- Cantor's Irina Rivkind is out defending Sucampo Pharmaceuticals (SCMP -2.4%) after a downgrade from Maxim sent the shares lower.
- Maxim cited lower priced Linzess (FRX, IRWD) as evidence of a "renewed competitive threat" to Amitiza.
- Rivkind says after checking with management, she is confident that "Ironwood has not taken a recent price decrease to compete with SCMP."
- "The competitor downgrade [is] misinformed, and an overreaction," in Rivkind's view.
- Buy rating reiterated.
From other sites
at Zacks.com (Apr 9, 2015)
at Zacks.com (Mar 16, 2015)
at Zacks.com (Mar 10, 2015)
at Benzinga.com (Dec 30, 2014)
at MarketWatch.com (Sep 26, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs